Clinical Trial

Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

Study acronym: COVSP-BCG
Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Human Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process COVID-19 target antigen protein into small peptide fragments, and then COVID-19 virus can be killed by APCs directly.
Protocol Amendment History 28 amendments
This ClinicalTrials.gov record has been amended 28 times since 2017-10-04; most recent amendment 2026-06-08.
Status change: Not Yet Recruiting → Active, Not Recruiting 2017-12-01
Trial Details
NCT Number NCT03305341
Lead Sponsor Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Collaborators: UnitedHealthcare
Conditions Covid19
Enrollment 20 participants
Start Date 2025-05-18
Primary Completion 2026-11-18 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-06-10